As global diabetes prevalence continues to rise, insulin production must scale while meeting strict GMP and sterility requirements. This case study explores how industrial insulin manufacturing is designed, from biotechnology to aseptic formulation, and how Boccard supported a major producer in reinforcing formulation capacity.

As demand for GLP‑1 therapies grows in obesity and Type 2 diabetes care, manufacturers must rapidly scale production while meeting strict GMP requirements. This case study shows how Boccard delivered a robust and scalable GLP‑1 production line.

Discover how E. coli recombinant protein fermentation scale up moves from 5 L glass to a 30 L seed and 150 L main bioreactor, with inline pH/DO/glucose analytics, CIP/SIP and compact centrifuge, sonication and ultrafiltration. A temperature and pH controlled waste inactivation tank enables safe discharge in a limited space. With TEKINBIO™ and Track Advance, teams gain tighter control and traceable scale‑up for reliable industrialisation.

For this greenfield project, Boccard carried out the entire project with a “global contractor” approach, thus integrating civil engineering, clean rooms, as well as all production units.

This company turned to Boccard for the piping package for its new microcrystalline cellulose (MCC) plant.

As part of a technology transfer between the French and Brazilian laboratory, Boccard was chosen as the supplier of the process equipment.

To increase its production capacity for plasma-derived drugs, LFB called on Boccard Health & Care.

Boccard carried out the design, manufacture, qualification and commissioning of a fermentation platform with a capacity of 1000L.